Grifols Purchases Novartis Transfusion Diagnostics Unit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Grifols Purchases Novartis Transfusion Diagnostics Unit


Grifols, a producer of plasma therapies, and Novartis have announced that Grifols will acquire the transfusion diagnostics unit of Novartis for $1.68 billion, according to a Grifols press release. The transaction is part of Grifols’ growth strategy of complementing its range of plasma protein therapies with other diagnostic products and services (Diagnostic Division). Assets acquired in the transaction include patents, brands, licenses, and royalties as well as a production plant in Emeryville, CA, and commercial offices in the United States, Switzerland, and Hong Kong (for the Asia-Pacific region) among others.

Grifols plans on expanding its portfolio by including Novartis’ diagnostic products for transfusion medicine and immunology, including its highly innovative, market-leading Nucleic Acid Amplification Techniques (NAT) technology, instrumentation, and equipment for blood screening, specific software, and reagents. The company hopes this strategic operation will strengthen Grifols’ Diagnostic Division, particularly in the US.

The company also expects Novartis’ diagnostic business, which focuses on guaranteeing the safety of blood donations for transfusion or to be used in the plasma fractionating industry, to complement Grifols’ existing bioscience division (plasma proteins). The company hopes to provide solutions for blood and plasma donor centers, with the most complete product portfolio in the immunohematology field: gel cards, multicard, and the new genotyping technology from Progenika.

“The acquisition of Novartis’ diagnostic business is a step further into our vision to become a world leader also in the diagnostics field,” said Victor Grifols, president and CEO of Grifols, in the press release. “To achieve this we knew we needed a significant presence in United States. We initiated the process in the Bioscience area in 2003 with the acquisition of the ATC assets and continued with the Talecris transaction in 2011. During the last two years the Diagnostic Division has been preparing for this step, especially in the immunohematology activities”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here